Search results for "prospective"

showing 10 items of 3738 documents

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

2013

The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from 4,973 tamoxifen-treated patients (12 globally distributed sites). Using strict eligibility requirements (postmenopausal women with estrogen receptor-positive breast cancer, receiving 20 mg/day tamoxifen for 5 years, criterion 1); CYP2D6 poor metabolizer status was associated with poorer invasive disease-free survival (IDFS: hazard ratio = 1.25; 95% confidence interval = 1.06, 1.47; P = 0.009). However, CYP2D6 status was not statistically significant when tamoxifen…

Oncologymedicine.medical_specialtyAntineoplastic Agents HormonalGenotypeBreast Neoplasms030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineBreast cancerInternal medicinemedicineHumansPharmacology (medical)skin and connective tissue diseasesProspective cohort studySurvival analysisAgedPharmacologyGynecologybusiness.industryHazard ratioGenetic VariationMiddle Agedmedicine.diseaseSurvival AnalysisConfidence interval3. Good healthTamoxifenTreatment OutcomeCytochrome P-450 CYP2D6Pharmacogenetics030220 oncology & carcinogenesisMeta-analysisFemaleMenopausebusinessTamoxifenPharmacogeneticsmedicine.drugClinical pharmacology and therapeutics
researchProduct

Neoadjuvant Chemo-Radiotherapy for Patients with Borderline Resectable Pancreatic Cancer: A Meta-Analytical Evaluation of Prospective Studies

2012

Context For patients with borderline resectable pancreatic cancer, the benefit of neoadjuvant therapy remains to be defined. Objective We did a systematic search of the literature on this topic. Methods Prospective studies, where chemotherapy, irrespective of regimen, in combination with radiotherapy was given before surgery to patients with borderline resectable cancer, were analyzed by a meta-analytical method. Primary outcome was tumor response; surgical exploration rate, resection rate, therapy-induced toxicity, and survival were secondary outcomes. Data were expressed as weighted pooled proportions with 95% confidence interval (95% CI). Results Eleven studies with 247 participants were…

Oncologymedicine.medical_specialtyChemo-radiotherapyMeeting Abstracts; PancreasHepatologybusiness.industryEndocrinology Diabetes and MetabolismGastroenterologymedicine.diseaseBorderline resectablePancreatic cancerInternal medicinemedicinebusinessProspective cohort study
researchProduct

First results for resetting the antitumor immune response by immune corrective surgery in colon cancer.

1998

BACKGROUND: A critical step for cancer recurrence is the failure of the cellular immune response. It is suspected that chronic humoral immune responses against some tumor-associated antigens (TAA) can contribute to that failure. METHODS: In this study, we tested the ability of an immune corrective surgical procedure to prevent recurrences of colon cancer in stages I, II, and III. Radiolabeled anti-TAG antibodies injected intravenously become concentrated on TAG-72 immune complexes presented by follicular dendritic cells, which are responsible for the persistent humoral response against TAG-72 TAA. Using a hand-held gamma probe, we can intraoperatively detect and remove lymph nodes involved …

Oncologymedicine.medical_specialtyColorectal cancerAntibodies NeoplasmImmune systemAntigenAntigens NeoplasmInternal medicineCarcinomamedicineHumansProspective StudiesLymph nodeNeoplasm StagingAntigen PresentationbiologyFollicular dendritic cellsbusiness.industryGeneral Medicinemedicine.diseasePrognosisSurvival Analysismedicine.anatomical_structureTreatment OutcomeRadioimmunodetectionImmunologyAntibody FormationColonic Neoplasmsbiology.proteinLymph Node ExcisionSurgeryLymphImmunotherapyLymph NodesAntibodyNeoplasm Recurrence LocalbusinessAmerican journal of surgery
researchProduct

Significance of P16INK4A hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (G…

2006

Background Methylation of the p16 promoter is one of the most frequent mechanisms of gene inactivation; its incidence is extremely variable according to the type of tumor involved. Our purpose was to analyze the hypermethylation of the p16 promoter in laryngeal squamous cell carcinomas (LSCC), salivary gland (SG) tumors and in colorectal cancer (CRC), to detect any possible association with the clinicopathological features and to determine the prognostic significance of the p16 gene in the tumors analyzed. Patients and methods The hypermethylation of the p16 promoter was prospectively analyzed, by MSP, in a consecutive series of 64 locally advanced LSCC patients, in a consecutive series of …

Oncologymedicine.medical_specialtyColorectal cancerInternal medicinemedicineHumansPromoter Regions GeneticProspective cohort studyNeoplasm StagingUnivariate analysisbusiness.industryGenes p16Incidence (epidemiology)CancerHematologyMethylationDNA Methylationmedicine.diseaseOncologyHead and Neck NeoplasmsSalivary gland cancerDNA methylationCarcinoma Squamous CellColorectal NeoplasmsbusinessP16INK4A head and neck carcinoma
researchProduct

Early Tumor Size Reduction of at least 10% at the First Follow-Up Computed Tomography Can Predict Survival in the Setting of Advanced Melanoma and Im…

2021

Early tumor size reduction (TSR) has been explored as a prognostic factor for survival in patients with advanced melanoma in clinical trials. The purpose of this analysis is to validate, in a routine clinical milieu, the predictive capacity of TSR by 10% for overall survival (OS) and progression-free survival (PFS) and to compare its predictive performance with the RECIST 1.1 criteria.This retrospective study was approved by the local ethics committee. A total of 152 patients with both CT before immunotherapy initiation and at first response evaluation after immunotherapy initiation were included. Prior to statistical analysis, treatment response was trichotomized as follows: Complete respo…

Oncologymedicine.medical_specialtyContext (language use)030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesProgression-free survivalProspective cohort studyMelanomaRetrospective Studiesbusiness.industryMelanomafungiRetrospective cohort studymedicine.diseaseClinical trialTreatment Outcome030220 oncology & carcinogenesisBiomarker (medicine)ImmunotherapyTomography X-Ray ComputedbusinessProgressive diseaseFollow-Up StudiesAcademic Radiology
researchProduct

Prognostic implications of extranodal extension in node-positive squamous cell carcinoma of the vulva: A systematic review and meta-analysis

2016

Squamous cell carcinoma (SCC) of the vulva is the fourth most common gynecological cancer, usually staged with the TNM or FIGO systems. Since 2009, FIGO staging has taken the extranodal extension (ENE) of lymph node metastases into account. ENE is defined as the spread of a lymph node metastasis into surrounding soft tissue. Although the TNM and FIGO systems acknowledge the importance of ENE in SCC, no comprehensive studies have analyzed the prognostic impact of this parameter. We therefore queried the PubMed and SCOPUS databases from their inception up until 04/01/2015, adopting no language restrictions: all prospective studies reporting on prognostic parameters in patients with vulvar SCC…

Oncologymedicine.medical_specialtyExtranodal metastasisVulva03 medical and health sciences0302 clinical medicineInternal medicineExtranodal extensionmedicineHumans030212 general & internal medicineProspective cohort studyLymph nodeGynecologyVulvar neoplasmVulvar NeoplasmsVulvar cancerbusiness.industryENE; Extranodal extension; Extranodal metastasis; Vulvar cancer; Oncology; SurgeryHazard ratioVulvar cancerENE; Extranodal extension; Extranodal metastasis; Vulvar cancermedicine.diseasePrognosisExtranodal metastasimedicine.anatomical_structureOncology030220 oncology & carcinogenesisMeta-analysisRelative riskCarcinoma Squamous CellENEFemaleSurgeryLymph Nodesbusiness
researchProduct

E-Cadherin gene expression in oral cancer: Clinical and prospective data

2019

Background Low protein expression of E-cadherin in oral squamous cell carcinoma (OSCC) has been associated with clinical and histopathological traits such as metastases, recurrence, low survival and poor tumor differentiation, and it is considered a high-risk marker of malignancy. However, it is still unknown whether low expression of E-cadherin is also present at the mRNA level in OSCC cases. Objective: The aim of this study was to compare E-cadherin mRNA expression in OSCC patients and controls and to correlate the expression with clinical and prospective characteristics. Material and Methods Forty patients and 40 controls were enrolled. E-cadherin mRNA expression was evaluated by quantit…

Oncologymedicine.medical_specialtyLow proteinMalignancyMetastasis03 medical and health sciences0302 clinical medicineInternal medicineGene expressionBiomarkers TumormedicineCarcinomaHumansProspective StudiesProspective cohort studyGeneral DentistryMouth neoplasmOral Medicine and PathologyE-Cadherinbusiness.industryResearchOral cancerCancer030206 dentistryCadherinsPrognosis:CIENCIAS MÉDICAS [UNESCO]medicine.diseasestomatognathic diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASCarcinoma Squamous CellMouth NeoplasmsSurgeryGene expressionNeoplasm Recurrence LocalbusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Quality of life after pulmonary stereotactic fractionated radiotherapy (SBRT): Results of the phase II STRIPE trial.

2019

Preserving health related quality of life (HRQOL) plays an important role in considering stereotactic body fractionated radiotherapy (SBRT). The prospective monocenter phase II STRIPE trial investigated long-term HRQOL after SBRT, efficacy and toxicity.Patients with ≤2 pulmonary lesions ≤5 cm were treated with 4DPET/CT-based SBRT (3 × 12.5 Gy or risk-adapted 5 × 7 Gy, to 60% isodose). Follow up (FU) was performed 2 and 7 weeks after SBRT, then 3-monthly for 2 years with assessment of response (primary endpoint: 2-year cumulative incidence of local progression (LP); secondary endpoints: local progression free survival (LPFS), overall survival (OS) and toxicity (CTCAE)). Impact of predefined …

Oncologymedicine.medical_specialtyLung NeoplasmsFractionated radiotherapyRadiosurgery030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicinemedicineClinical endpointHumansRadiology Nuclear Medicine and imagingCumulative incidenceProgression-free survivalProspective StudiesLung cancerHealth related quality of lifebusiness.industryHematologymedicine.diseasehumanitiesRegimenOncology030220 oncology & carcinogenesisQuality of LifeDose Fractionation RadiationbusinessRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
researchProduct

1480P M2 macrophages could promote an immunosuppressive phenotype in a prospective cohort of advanced gastric cancer patients

2020

Oncologymedicine.medical_specialtyOncologybusiness.industryInternal medicineMedicineHematologyAdvanced gastric cancerbusinessProspective cohort studyPhenotypeAnnals of Oncology
researchProduct

Osteonecrosis of the jaws produced by sunitinib : a systematic review

2019

Background Tyrosine kinase receptor family is involved in tumor growth, pathological angiogenesis and the progression (metastasis) of cancer. Sunitinib (Sutent®) inhibits members of the tyrosine kinase receptor family affecting the induction of angiogenesis and tumor progression. It is not clear if sunitinib increases the risk of osteonecrosis of the jaws (ONJ). The aim of this study was to carry out a systematic review about ONJ related to sunitinib, describing existing cases and possible associated risk factors. Material and Methods The PubMed/MEDLINE and Cochrane Library databases were searched without date restriction up to September 2018. We included prospective and retrospective obser…

Oncologymedicine.medical_specialtyPopulationMEDLINEReviewCochrane Library03 medical and health sciences0302 clinical medicineInternal medicineSunitinibmedicineHumansProspective StudieseducationProspective cohort studyGeneral DentistryRetrospective Studieseducation.field_of_studyOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesSunitinibbusiness.industryOsteonecrosisRetrospective cohort study030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Cross-Sectional StudiesDenosumabOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryObservational studybusinessmedicine.drug
researchProduct